MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
Rhea-AI Summary
MannKind (Nasdaq: MNKD) will release its third quarter 2025 financial results before the market opens on November 5, 2025. The company will host a webcast at 9:00 a.m. Eastern Time the same day to discuss results and provide a business update.
Investors can access the live webcast and a replay via the company’s investor website at https://investors.mannkindcorp.com/events-and-presentations; the replay will be available within 24 hours and remain accessible for approximately 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – MNKD
In the Oct 30 session, MNKD gained 0.18%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.4% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2025 financial results will be released before the market opens on November 5, 2025.
MannKind will host a webcast beginning at 9 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.
MannKind Contacts: Investor Relations Ana Kapor Email: ir@mnkd.com Media Relations Christie Iacangelo Email: media@mnkd.com